Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”CD68 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
Oncology research laboratories, immunology centers, and clinical pathology departments face a critical analytical requirement: specific detection of macrophages and monocytes — key immune cells involved in inflammation, tissue remodeling, and tumor progression — to study the tumor microenvironment (TME), assess inflammatory conditions, and evaluate therapeutic responses. CD68 antibody directly addresses this need. CD68 (macrosialin in mice, also known as GP110) is a highly glycosylated transmembrane protein expressed predominantly on lysosomes and endosomes of monocytes, macrophages, osteoclasts, and other phagocytic cells. It is the most widely used pan-macrophage marker for immunohistochemistry (IHC) of formalin-fixed, paraffin-embedded (FFPE) tissue sections, where its strong cytoplasmic granular staining pattern reliably identifies tissue macrophages. CD68 antibodies are available in monoclonal (high specificity) and polyclonal formats, with applications in IHC for tumor-associated macrophage (TAM) quantification, immunofluorescence for co-localization studies, and flow cytometry for phagocytic cell analysis. This deep-dive analysis evaluates market dynamics, monoclonal vs. polyclonal segmentation, and adoption across cancer research, inflammation studies, and diagnostic applications.
The global market for CD68 antibody was estimated to be worth US58millionin2025andisprojectedtoreachUS58millionin2025andisprojectedtoreachUS 85 million by 2032, growing at a CAGR of 5.6% from 2026 to 2032. Growth is driven by increasing cancer immunotherapy research (tumor microenvironment, macrophage polarization), expansion of IHC-based prognostic biomarker panels for solid tumors (breast, colorectal, lung, ovarian), and growing demand for validated FFPE-compatible antibodies in diagnostic pathology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985673/cd68-antibody
1. Core Technical Applications and Detection Formats
CD68 antibodies are used across multiple platforms with specific requirements for tissue compatibility:
| Application | Primary Use | Key Clone/Specificity | Critical Parameter | Typical Format |
|---|---|---|---|---|
| Immunohistochemistry (IHC) | Tumor-associated macrophage (TAM) quantification, inflammation assessment | Monoclonal (KP1, PG-M1, 514H12) | Validated on FFPE sections, strong cytoplasmic granular staining, minimal background | HRP/DAB (brown), alkaline phosphatase (red), fluorescent |
| Immunofluorescence (IF) | Macrophage co-localization (CD68 with CD163, CD206, iNOS) | Monoclonal (KP1, PG-M1) | Low background, multiple species compatibility (human, mouse, rat) | Alexa Fluor (488, 555, 647), Cy3, FITC conjugates |
| Western Blot (WB) | CD68 protein detection (110 kDa) | Monoclonal (KP1, EPR17335) | Denatured epitope recognition, specific band at 110kDa (deglycosylated ~75kDa) | HRP, AP conjugates |
| Flow Cytometry | Macrophage identification in single-cell suspensions | Monoclonal (Y1/82A, eBioY1/82A) | Cell surface/cytoplasmic staining (perm fixation required), bright fluorophore | FITC, PE, APC, PerCP-Cy5.5 conjugates |
独家观察 (Exclusive Insight): While most market analysis focuses on CD68 as a standard IHC marker, the fastest-growing segment since Q4 2025 is multiplex IHC panels for spatial phenotyping of tumor-associated macrophages (TAMs) . The clinical field recognizes that CD68 alone cannot distinguish M1 (pro-inflammatory/anti-tumor) from M2 (pro-tumor/immunosuppressive) macrophages. A January 2026 consensus publication from the Society for Immunotherapy of Cancer (SITC) recommended CD68 as the lineage marker combined with CD86 (M1) and CD163 or CD206 (M2) for spatial TAM profiling. This has driven demand for validated CD68 clones (KP1, PG-M1) optimized for multiplex staining platforms (Akoya Vectra, Leica BOND, Roche Ventana) with compatibility for 4-8 color brightfield and fluorescent panels. Multiplex-optimized CD68 antibodies (pre-tested with CD163, CD206, PD-L1, FoxP3 panels) command 2-3x price premiums (500−1,000per100testsvs.500−1,000per100testsvs.200-400 for single-plex IHC), and suppliers with multi-tissue validation on tumor microarrays are capturing this high-value sub-segment. Bio-Rad, Abcam, and Cell Signaling Technology all launched multiplex-optimized CD68 clones in Q4 2025.
2. Segmentation: Monoclonal vs. Polyclonal
| Segment | 2025 Share | Key Advantages | Primary Applications | Average Price per 100 μg |
|---|---|---|---|---|
| Monoclonal | 78% | Single epitope specificity, consistent batch-to-batch, validated for FFPE IHC (KP1, PG-M1), low background | Clinical IHC (TAM quantification), diagnostic pathology, multiplex panels | 250−250−600 |
| Polyclonal | 22% | Multiple epitope recognition, higher signal for WB, broader species cross-reactivity | Western blot, research IHC (where clone validation not critical) | 150−150−350 |
Monoclonal antibodies dominate (78% share) because clinical and translational research requires reproducible staining intensity and localization (cytoplasmic/granular) across large patient cohorts. Clone KP1 (mouse IgG1) is the most widely validated CD68 antibody for FFPE human IHC; clone PG-M1 offers advantages on certain automated staining platforms. Polyclonal antibodies retain share in WB applications and cross-species studies.
3. Application Analysis: Cancer TAM Research, Inflammation Studies, Diagnostic IHC
Cancer Tumor Microenvironment Research (TAM Quantification) (48% of 2025 demand): Largest segment. A Q4 2025 study of 420 triple-negative breast cancer (TNBC) patients used CD68 IHC (clone KP1) plus CD163 IHC for TAM density quantification, correlating high CD68+/CD163+ ratio with worse overall survival (HR=2.4, p<0.001). Research requirement: validated for FFPE IHC (automated stainer compatibility), strong cytoplasmic/granular staining (no membrane misinterpretation), and compatibility with TMA (tissue microarray) formats.
Inflammation and Autoimmune Research (22% of demand): Rheumatoid arthritis synovial tissue, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), and atherosclerosis plaque analysis. A January 2026 study of Crohn’s disease biopsies used CD68/CD206 dual IF to demonstrate M2 macrophage predominance in fibrostenotic lesions. Inflammation requirement: compatibility with frozen tissue sections (some clones lose reactivity), species cross-reactivity (human, mouse, rat), and co-localization suitability (bright fluorescent conjugates).
Diagnostic Pathology (15% of demand): Clinical immunohistochemistry for macrophage-rich lesions (granulomatous diseases, xanthogranulomatous inflammation) and research-use-only prognostic panels for clinical trials. Diagnostic requirement: CE-IVD or FDA Research Use Only (RUO) labeling, batch-to-batch consistency (<10% staining intensity CV), and validated on specific autostainers (Leica BOND, Roche Ventana, Dako Omnis).
Industry Layering Insight: In cancer research TAM quantification (high-volume, high multiplex), monoclonal CD68 (KP1 or PG-M1) validated for 4-8 color multiplex IHC with TAM polarization markers (CD163, CD206, iNOS, Arg1) drives purchasing. In clinical diagnostic pathology (regulated), IVD-cleared or RUO CD68 clones with lot consistency on automated platforms are required. In inflammation research (multi-species), cross-reactive monoclonal or polyclonal antibodies with IF compatibility are prioritized.
4. Competitive Landscape and Technical Challenges
Key Suppliers: BosterBio, Leinco Technologies, Bioss Inc, GeneTex, HUABIO, Novus Biologicals, Merck (Sigma-Aldrich), Thermo Fisher Scientific, Bio-Rad (AbD Serotec), Abnova Corporation, Enzo Life Sciences, Beijing Solarbio Science & Technology, Abcam, Cell Signaling Technology, Agilent (Dako), Roche (Ventana).
Technical Challenges: Epitope sensitivity to fixation — CD68 is highly sensitive to formalin fixation and antigen retrieval conditions. Clone KP1 requires high-temperature (98-100°C) citrate or Tris-EDTA retrieval, pH 6.0 or 9.0 depending on clone. Inadequate retrieval yields false-negative results. Cytoplasmic endosomal staining interpretation — CD68 stains cytoplasmic lysosomal/endosomal vesicles, not the plasma membrane. This granular pattern can be misinterpreted by inexperienced pathologists as background or necrosis. Cross-reactivity with other cell types — low-level CD68 expression in some dendritic cells and certain tumor cells (e.g., melanoma, renal cell carcinoma) requires careful interpretation. CD68 KO controls or double staining with CD163 are recommended for specificity confirmation.
Recent Developments (2025–2026):
- Bio-Rad (December 2025) launched CD68 (clone KP1) in “Multiplex IHC Panel-Ready” format with 20 pre-optimized staining protocols for Leica BOND and Roche Ventana platforms
- Cell Signaling Technology (January 2026) introduced recombinant rabbit monoclonal CD68 antibody (clone D4B9C) with enhanced specificity vs. mouse monoclonals (lower background on FFPE)
- Agilent Dako (Q4 2025) received CE-IVD certification for CD68 (clone PG-M1) for automated IHC on Dako Omnis platform
- SITC (October 2025) published “Tumor-Associated Macrophage Multiplex IHC Consensus Panel” recommending CD68 as lineage marker in 6-color TAM panel
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $58M | $85M | 5.6% |
| Monoclonal share | 78% | 82% | — |
| Cancer TAM research share | 48% | 52% | — |
| Multiplex-optimized share | ~12% | ~28% | — |
| North America market share | 45% | 42% | — |
| Asia-Pacific market share | 20% | 28% | — |
- Fastest-growing region: Asia-Pacific (CAGR 7.0%), led by China (cancer research funding growth, multiplex IHC expansion) and Japan/South Korea (TME research)
- Fastest-growing segment: Multiplex panel-optimized CD68 antibodies (CAGR 12-14%), driven by TAM spatial profiling in immuno-oncology clinical trials
- Price trends: Standard monoclonal CD68 for IHC has declined 2-3% annually; multiplex-optimized and IVD-grade antibodies stable or increasing (+2-3%)
Conclusion
CD68 antibody is the gold standard pan-macrophage marker for IHC-based TAM quantification in cancer research, inflammation studies, and diagnostic pathology. Global Info Research recommends that cancer TAM researchers (multiplex IHC) select multiplex-optimized monoclonal clones (KP1, PG-M1) pre-validated with CD163/CD206 panels on automated platforms; diagnostic pathology labs require IVD/RUO clones with batch consistency and autostainer validation; inflammation researchers should verify species cross-reactivity and frozen tissue compatibility. As TAM spatial profiling becomes standard in immuno-oncology trials, multiplex-optimized CD68 antibodies represent the highest-growth sub-segment.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
